Clinical Trials Logo

Filter by:
NCT ID: NCT06222645 Recruiting - Perfusion Clinical Trials

PPG vs. ICG in Gastrointestinal Resections

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

In this study, gastrointestinal anastomoses are examined with imaging Photoplethysmography and after this the investigators use the Standard Routine ICG-Imaging. At the end, both methods will be compared.

NCT ID: NCT06222125 Recruiting - Renal Cancer Clinical Trials

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Start date: January 30, 2023
Phase: Phase 2
Study type: Interventional

It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).

NCT ID: NCT06222008 Recruiting - Ovarian Cancer Clinical Trials

Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution

Start date: January 30, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about in Patients treated with postoperative chemotherapy for ovarian tumors. The main questions it aims to answer are: • [What symptom clusters are present in patients treated with postoperative chemotherapy for ovarian tumors] • [Are there differences in symptom clusters for patients with different TCM body types] Participants will [complete questionnaires prior to the start of chemotherapy and after the 1st, 3rd, and 6th chemotherapy treatments].

NCT ID: NCT06221982 Recruiting - Cirrhosis Portal Clinical Trials

TIPS for PH Patients: an Observational, Cohort Study

Start date: January 1, 2021
Phase:
Study type: Observational

This is a single-center, prospective, observational study intended to include patients receiving TIPS for portal hypertension. Baseline data of enrolled patients were recorded, and samples of ascites, feces and urine were collected before surgery. Venous blood (superior mesenteric vein, hepatic vein, peripheral vein) from different parts of the entero-hepatic axis was retained during operation, and patients were followed up regularly for 2 years. The incidence of infection, hepatic encephalopathy, upper gastrointestinal hemorrhage and ascites in patients with portal hypertension who received TIPS intervention were observed within 3 months after operation. And the stent patency was observed within 2 years after surgery. To investigate the characteristics of microbial, protein and metabolic components on enterohepatic axis and their relationship with prognosis of patients with cirrhosis by detecting microbiome, proteome and metabolome.

NCT ID: NCT06221891 Recruiting - Clinical trials for Chronic Kidney Diseases

Early Evaluation of Left Ventricular Systolic Function Impairment in Patients With Chronic Kidney Disease by Multimodal Ultrasonography

Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the value of multimodal ultrasound in early detection of left ventricular systolic dysfunction in patients with chronic kidney disease(CKD). The main questions it aims to answer are: 1. If first-phase ejection fraction(EF1)could early detect the left ventricular systolic dysfunction in patients with CKD. 2. Whether EF1 can detect left ventricular systolic dysfunction in patients with CKD more sensitively than speckle-tracking echocardiography and myocardial work. Participants will need to cooperate to do an echocardiography. Researchers will compare healthy volunteers and patients with CKD to see if EF1 could early detect the left ventricular systolic dysfunction.

NCT ID: NCT06221787 Recruiting - Melasma Clinical Trials

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.

NCT ID: NCT06221748 Recruiting - Gastric Cancer Clinical Trials

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Start date: February 22, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.

NCT ID: NCT06221722 Recruiting - Clinical trials for Constipation - Functional

Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation

Start date: November 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are: - Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients - Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation. Participants will receive: - Standard physiological and psychological assessments of constipation - BOLD-fMRI tests - Standard protocol and fluoxetine treatment If there is a comparison group: Researchers will compare: Refractory group/Fluoxetine sensitive group to see the specific brain alterations.

NCT ID: NCT06221683 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

GMCAII
Start date: March 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.

NCT ID: NCT06221423 Recruiting - Colorectal Cancer Clinical Trials

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.